Immunocore (IMCR) CEO sells shares and receives major RSU, option grants
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Immunocore Holdings plc chief executive officer Bahija Jallal reported several equity transactions. She sold 11,474 Ordinary Shares in an open-market transaction at a weighted average price of $32.35 per share, under a sell-to-cover arrangement to pay income taxes triggered by vesting restricted share units.
On a separate date, she acquired 23,817 Ordinary Shares at no cost through the exercise of Restricted Share Units, with each RSU converting into one Ordinary Share. She was also granted 88,573 new RSUs and 395,066 employee share options, each award vesting in scheduled installments starting in February 2026 or February 2027, contingent on continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 11,474 shares ($371,184)
Net Sell
5 txns
Insider
Jallal Bahija
Role
CHIEF EXECUTIVE OFFICER
Sold
11,474 shs ($371K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 11,474 | $32.35 | $371K |
| Exercise | Restricted Share Units | 23,817 | $0.00 | -- |
| Grant/Award | Restricted Share Units | 88,573 | $0.00 | -- |
| Grant/Award | Employee Share Option (Right to Buy) | 395,066 | $0.00 | -- |
| Exercise | Ordinary Shares | 23,817 | $0.00 | -- |
Holdings After Transaction:
Ordinary Shares — 12,343 shares (Direct);
Restricted Share Units — 71,453 shares (Direct);
Employee Share Option (Right to Buy) — 395,066 shares (Direct)
Footnotes (1)
- Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted share units ("RSUs"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.17 to $32.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Each RSU represents a contingent right to receive one Ordinary Share. On February 17, 2025, the Reporting Person was granted 95,270 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date. The RSUs vest in four equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service through each such vesting date. 25% of the shares subject to the option award shall vest on February 17, 2027, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
FAQ
What insider transactions did Immunocore (IMCR) CEO Bahija Jallal report?
Bahija Jallal reported selling 11,474 Ordinary Shares and acquiring equity awards. She exercised 23,817 Restricted Share Units into Ordinary Shares and received new grants of 88,573 RSUs and 395,066 employee share options, all under her compensation arrangements.